

Date: 8 August, 2024

To,

Corporate Relationship Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
Mumbai-400 051

**Scrip Code: BSE - 530549/ Stock Symbol: NSE – SHILPAMED**

Dear Sir/ Ma'am,

**Sub: Regulation 33, 34 and 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**

With reference to the captioned subject, this is to inform that the Board of Directors at their meeting held today i.e., on 8 August, 2024 which commenced at 11:27 AM and concluded at 02:30 PM have inter alia considered and approved the following:

1. The Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30 June, 2024. A Copy of the Un-Audited Financial Results along with the Limited Review report is enclosed as Annexure 1.
2. Reappointment of Mr. Vishnukant C Bhutada (DIN: 01243391) as Managing Director of the Company and Shilpa Pharma Lifesciences Limited, a Material Subsidiary of Shilpa Medicare Limited subject to Members approval in the ensuing AGM.
3. Reappointment of Mr. Hetal Madhukant Gandhi (DIN: 00106895) as Independent Director of the Company subject to Members approval in the ensuing AGM.
4. Re-designating Mr. Keshav Bhutada (DIN 08222057) as Executive Director in Shilpa Pharma Lifesciences Ltd, a Material Subsidiary, w.e.f 19 June 2024 subject to Members approval in the ensuing AGM.
5. Reappointment Mr. Madhav Bhutada (DIN: 08222055) as Managing Director of Shilpa Biocare Private Ltd., a Wholly Owned Subsidiary, w.e.f 1 October, 2024 subject to Members approval in the ensuing AGM.
6. Reappointment of Mr. Omprakash Inani (DIN: 01301385) Non-Executive Director, liable to retire by rotation and who being eligible offers himself for reappointment subject to Members approval in the ensuing AGM.
7. Payment of Remuneration/Commission payable to Non-Executive Directors subject to Members approval in the ensuing AGM.
8. Payment of remuneration to Mr. Hetal Madhukant Gandhi (Din: 00106895) Independent Director in excess of remuneration paid to all Non-Executive Directors subject to Members approval in the ensuing AGM.
9. Notice of Annual General Meeting of the Members of the Company

We are pleased to inform you that the 37 Annual General Meeting of Shilpa Medicare Limited is scheduled on Tuesday, the 17 day of September 2024 at 10:00 AM through video conferencing (VC)/ other audio-visual means (OAVM) to transact the business(es) as set forth in the notice of the meeting.

Cut-off date for determining the list of members for voting and participation at AGM through video conferencing (VC)/ other audio-visual means (OAVM) is set as Wednesday, 11 September, 2024

The Company is providing remote e-voting facility to the members in respect of resolutions to be passed at the AGM and has engaged the services of M/s KFin Technologies Limited for the said purpose.

In line with the provisions of Regulation 42 of SEBI (Listing obligations & disclosure requirements) Regulations, 2015 the record date for the AGM is set as Friday, 13 September 2024 and pursuant to Section 91 of the Companies Act, 2013 the Books of the Company shall remain closed w.e.f., Monday, 9 September 2024 to Tuesday, 17 September 2024

**Please find the below calendar set in terms of the Companies Act, 2013 and the rules framed thereunder read with SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015 for your reference:**

<b>PARTICULARS OF EVENTS</b>	<b>SCHEDULED DATES</b>
Record date	Friday, 13 September 2024
Book Closure	Monday, 9 September 2024 to Tuesday, 17 September 2024
Cut-off date for voting by the members and participation in AGM through VC.(The members of the record as on cut-off date would be eligible to cast their votes through remote e-voting and e-voting during the AGM)	Wednesday, 11 September 2024
Remote e-voting will commence on	Saturday, 14 September 2024 at 09:00 am
Remote e-Voting will end on	Monday, 16 September 2024 at 05:00 pm
Date of Speaker Registration & Posting of queries	Saturday, 14 September 2024 to Sunday, 15 September 2024
Day, date and time of AGM	Tuesday, 17 September 2024 at 10:00 am
Website of the service provider (Kfin) for e-voting	<a href="https://evoting.kfintech.com">https://evoting.kfintech.com</a>

It is to be noted that Mr. Ajay Vemuri, partner of M/s VCAN & Associates, Practicing Company Secretaries, having members hip number F11106 and COP 15460 is appointed as Scrutinizer for scrutinizing the evoting and INSTA poll process under the Companies Act 2013 for the ensuing Annual General Meeting to be held on 17 September, 2024

**For and on behalf of Shilpa Medicare Limited**

**Ritu Tiwary**  
**Company Secretary & Compliance Officer**



## Shilpa Medicare Limited

Registered office: # 12-6-214/A-1, Hyderabad Road, Raichur- 584135, Karnataka, India

Website - www.vbshilpa.com, Email - info@vbshilpa.com. , Telephone -+91-8532-238494

CIN No. - L85110KA1987PLC008739

### STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

(Rs. In Lakhs, except per equity share data)

Sl. No.	Particulars	Quarter ended			Previous year ended
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	<b>Income</b>				
	<b>Revenue from operations</b>	4,741.50	5,936.44	3,783.13	18,339.34
	a) Net Sales/income from operations		5,936.44	3,783.13	18,339.34
	b) Service Income and License fees	4,741.50			
	<b>Other Income</b>	3,145.44	2,324.67	2,078.23	8,911.60
	<b>Total Income</b>	7,886.94	8,261.11	5,861.36	27,250.94
2	<b>Expenses</b>				
	a) Cost of material consumed	1,420.23	2,713.09	1,400.50	7,386.89
	b) Purchase of stock-in-trade	129.51	411.54	255.51	1,274.89
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	817.45	123.01	307.85	263.46
	d) Employee benefits expense	2,636.03	2,428.03	2,779.78	10,363.85
	e) Finance cost	194.93	271.07	675.99	1,725.66
	f) Depreciation and amortisation expenses	1,230.21	1,228.69	1,226.28	4,961.09
	g) Other expenses	2,213.88	2,373.49	2,096.58	9,060.41
	<b>Total Expenses</b>	8,642.24	9,548.93	8,742.49	35,036.25
3	<b>Profit before tax and exceptional items (1-2)</b>	- 755.30	- 1,287.82	- 2,881.13	- 7,785.32
4	Exceptional items- (Income)/Expenses (Pl refer note no: 04)	46.00	378.35	633.74	1,045.10
5	<b>Profit before tax (3+4)</b>	- 801.30	- 1,666.17	- 3,514.87	- 8,830.41
6	<b>Tax expense</b>	1,234.29	168.77	286.12	1,115.17
	-Current tax	1,120.37	218.48	188.02	1,128.65
	-Deferred tax (Net of MAT credit )	113.92	(49.72)	98.10	(13.48)
7	<b>Net profit for the period/year (5-6)</b>	- 2,035.59	- 1,834.94	- 3,800.99	- 9,945.58
8	<b>Other comprehensive income/ (loss)</b>				
	<b>a. Items that will not be reclassified subsequently to profit or loss</b>	-	(165.63)	-	(165.63)
	Remeasurement of the defined benefit (liability)/asset	-	(254.58)	-	(254.58)
	Income Tax relating to the above	-	88.95	-	88.95
	<b>b. Items that will be reclassified subsequently to profit or loss</b>	-	-	-	-
	<b>Total other comprehensive income/(loss) (net of tax)(a+b)</b>	-	(165.63)	-	(165.63)
9	<b>Total comprehensive income for the period / year (7+8)</b>	- 2,035.59	- 2,000.57	- 3,800.99	- 10,111.22
10	Paid up equity share capital (par Value Rs.1/- each, fully paid )	977.91	868.02	868.02	868.02
11	<b>Reserves i.e Other equity</b>				2,13,403.80
12	<b>Earnings per equity share (par value Rs.1/- each):</b>	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	Basic (Rs.)	2.94	2.11	4.38	11.46
	Diluted (Rs.)	2.94	2.11	4.38	11.46

For and on behalf of the Board of Directors

Shilpa Medicare Limited

  
Omprakash Inani

Chairman

DIN:01301385



Date: 08.08.2024

Place: Raichur



**BOHARA BHANDARI BUNG & ASSOCIATES LLP**  
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors of Shilpa Medicare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Shilpa Medicare Limited ("the Company") for the quarter ended June 30, 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations"). ("the Statement") attached herewith.
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We draw your attention to note no 06 in respect of unfavourable foreign arbitration award of Rs.3,738.63 Lakhs to Celltrion Inc by ICC International Court of Arbitration, London vide its order dated 22.01.2024. towards breach of contract along with legal cost and interest calculated upto June 30<sup>th</sup> 2024, Celltrion has filed an execution petition before the Honorable High court of Karnataka, Bengaluru, on June 03, 2024. Based on the legal advice, the Company has challenged the execution petition. Hence, the ultimate outcome of the order cannot be determined presently. Therefore, the management is of the view that no provision is deemed necessary as of now in respect of this matter in the Financial Statements and the same is disclosed as a contingent liability.

Our opinion is not modified in respect of this matter.





**BOHARA BHANDARI BUNG & ASSOCIATES LLP**  
CHARTERED ACCOUNTANTS

4. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind-AS') specified under sec.133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India, and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Bohara Bhandari Bung And Associates LLP**  
Chartered Accountants  
Firm Regn No.008127S/S200013



**CA. Yogesh R. Bung**  
Partner  
M.No.143932

Place: Raichur

Date: 08.08.2024

UDIN: 24143932BKAESL7383



Innovating for  
affordable healthcare

## Shilpa Medicare Limited

Registered office : # 12-6-214/A-1, Hyderabad Road, Raichur -584135, Karnataka, India

Website - www.vbshilpa.com, Email - info@vbshilpa.com. , Telephone --+91-8532-238494

CIN No. - L85110KA1987PLC008739

### STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

(Rs. In Lakhs, except per equity share data)

SI No.	Particulars	Quarter ended			Previous year ended
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	<b>Income</b>				
	<b>Revenue from operations</b>	<b>29,251.06</b>	<b>29,169.25</b>	<b>26,017.46</b>	<b>1,15,160.30</b>
	a) Net Sales/income from operations	21,231.74	23,763.52	19,754.31	93,533.24
	b) Service Income and License fees	8,019.31	5,405.73	6,263.15	21,627.06
	<b>Other Income</b>	<b>944.29</b>	<b>249.38</b>	<b>193.10</b>	<b>817.05</b>
	<b>Total Income</b>	<b>30,195.35</b>	<b>29,418.63</b>	<b>26,210.56</b>	<b>1,15,977.35</b>
2	<b>Expenses</b>				
	a) Cost of material consumed	7,676.41	10,116.30	9,515.19	42,431.76
	b) Purchase of stock-in-trade	275.96	535.66	406.06	1,801.39
			(944.16)	(1103.74)	(3477.76)
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	1,328.33			
	d) Employee benefits expense	7,214.17	6,645.93	7,287.67	28,149.31
	e) Finance cost	2,373.80	2,420.37	1,815.12	9,180.94
	f) Depreciation and amortisation expenses	2,710.68	2,662.51	2,674.60	10,786.99
	g) Other expenses	5,396.32	5,809.69	5,120.34	21,805.89
	<b>Total Expenses</b>	<b>26,975.68</b>	<b>27,246.30</b>	<b>25,715.24</b>	<b>1,10,678.51</b>
3	<b>Profit before share of profit of joint venture and associates, exceptional items and tax (1)-(2)</b>	<b>3,219.67</b>	<b>2,172.34</b>	<b>495.32</b>	<b>5,298.84</b>
4	Share of Profit / (loss) of Joint venture and associates, net of tax	(351.72)	(14.03)	(166.31)	(477.84)
5	<b>Profit before tax and exceptional items (3-4)</b>	<b>2,867.95</b>	<b>2,158.30</b>	<b>329.01</b>	<b>4,821.00</b>
6	Exceptional items- (Income)/Expenses (Pl refer note no: 04)	-	(613.07)	-	(613.07)
7	<b>Profit Before Tax (5+6)</b>	<b>2,867.95</b>	<b>2,771.37</b>	<b>329.01</b>	<b>5,434.07</b>
8	<b>Tax Expense</b>	<b>1,461.74</b>	<b>321.08</b>	<b>211.35</b>	<b>2,238.55</b>
	-Current tax	1,590.96	1,125.96	884.61	4,529.50
	-Deferred tax ( Net of MAT credit )	(129.22)	(804.88)	(673.26)	(2290.95)
9	<b>Profit for the Period / year before non-controlling interest (7)-(8)</b>	<b>1,406.21</b>	<b>2,450.29</b>	<b>117.66</b>	<b>3,195.52</b>
10	Share of (loss)/profit attributable to non-controlling interest	0.00	(0.00)	0.25	(8.09)
11	<b>Profit after taxes attributable to owners of the Parent Company for the period / year (9-10)</b>	<b>1,406.21</b>	<b>2,450.29</b>	<b>117.91</b>	<b>3,187.42</b>
12	<b>Other comprehensive income/ (loss)</b>				
	<b>A. Items that will not be reclassified subsequently to profit or loss</b>	<b>2.85</b>	<b>(240.23)</b>	<b>1.05</b>	<b>(237.06)</b>
	Remeasurement of the defined benefit (liability)/asset	3.85	(350.09)	1.43	(346.92)
	Income tax relating to the above	(1.00)	109.86	(0.37)	109.86
	<b>B. Items that will be reclassified subsequently to profit or loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>Total other comprehensive income(net of tax)(A+B)</b>	<b>2.85</b>	<b>(240.23)</b>	<b>1.05</b>	<b>(237.06)</b>
13	<b>Total comprehensive income for the period / year (11)+(12)</b>	<b>1,409.06</b>	<b>2,210.06</b>	<b>118.96</b>	<b>2,950.36</b>
14	Paid up equity share capital (par Value Rs.1/- each, fully paid )	977.91	868.02	868.02	868.02
15	Reserves i.e other equity				<b>1,80,001.39</b>
16	<b>Earnings per equity share (par value Rs.1/- each)</b>	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	Basic (Rs.)	1.46	2.82	0.14	3.67
	Diluted (Rs.)	1.46	2.82	0.14	3.67



**Notes:**

- 1 The above statement of unaudited standalone and consolidated financial results for the quarter ended June 30, 2024 in respect of Shilpa Medicare Limited ("the Company") were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 08, 2024. The Statutory Auditors have carried out a limited review on the above results and expressed an unmodified opinion on the said results.
- 2 These financial results have been prepared in accordance with Indian Accounting Standards ('Ind-AS') notified under section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015 (as amended).
- 3 During the year ended March 31, 2024, the Group has raised Rs.45,000.00 Lakhs by issue of unlisted secured Non-Convertible Debentures on private placement basis. These debentures are repayable in quarterly installments starting from the expiry of 24 months and upto 60 months from the date of its issue. Additionally, the promoters have given a Non-disposal undertaking (NDU) in respect of their equity shares against such debentures.
- 4 **Exceptional Items:**
  - a Exceptional loss in current quarter ended June 30, 2024 of Rs 46.00 Lakhs in standalone is on account of :
    - i. Rs.15.69 Lakhs is on account of provision for impairment loss of interest accrued for the current quarter ended 30.06.2024 but not due on advance to Indo Biotech SDN.BHD, Malaysia, a wholly owned foreign subsidiary.
    - ii. Rs.11.55 Lakhs is on account of provision for impairment loss of interest accrued for the current quarter ended 30.06.2024 but not due on advance to Koanna International FZ LLC, Dubai, a wholly owned foreign subsidiary.
    - iii. Rs.18.75 Lakhs is on account of provision for impairment loss of interest accrued for the current quarter ended 30.06.2024 but not due on advance to Koanna Healthcare GmbH, Austria, a wholly owned foreign subsidiary, which has been provided for in the books
  - b Exceptional loss in previous year quarter ended March 31, 2024 of Rs.378.35 Lakhs in standalone is on account of :
    - i. Rs.37.55 Lakhs provision for impairment loss of interest accrued but not received and exchange fluctuation on advance reinstating of Koanna International FZ LLC, Dubai, a wholly owned foreign subsidiary.
    - ii. Rs.340.80 Lakhs provision towards impairment losses on account of investment in, advance to, Interest accrued but not received and exchange fluctuation on advance reinstating of Indo Biotech SDN.BHD, Malaysia, a wholly owned foreign subsidiary.
  - c Exceptional loss in previous year quarter ended June 30, 2023 of Rs.633.74 Lakhs in standalone is on account of provision for impairment losses on account of investment in and advance to Koanna International FZ-LLC, Dubai, a wholly owned foreign subsidiary.
  - d Exceptional loss in previous year quarter ended March 31, 2024 of Rs.1,045.10 Lakhs in standalone is on account of :
    - i. Rs.704.30 Lakhs is on account of provision for impairment losses on account of investment in, advance to, interest accrued but not received and exchange fluctuation on advance reinstating of Koanna International FZ LLC, Dubai, a wholly owned foreign subsidiary.
    - ii. Rs.340.80 Lakhs provision towards impairment losses on account of investment in, advance to, Interest accrued but not received and exchange fluctuation on advance reinstating of Indo Biotech SDN.BHD, Malaysia, a wholly owned foreign subsidiary.
  - e During previous year quarter and year ended March 31, 2024, the Group through its wholly owned subsidiary Vegil Labs Private Limited has sold the entire stake in Auxilla Pharmaceuticals and Research LLP (amounting to 40% of the entire capital) for a consideration of Rs.1,100.00 Lakhs. Consequently, during the said quarter, the Group has recognised a gain of Rs.613.07 Lakhs after considering its share of loss upto March 5, 2024 in the consolidated financial results.
- 5 During current quarter ended June 30, 2024, the Company has issued 1,09,89,010 Equity shares of face value Rs.1 each at a issue price of Rs 455.00 Per equity share pursuant to Qualified Institutions Placement (QIP) under the provisions of Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "SEBI ICDR Regulations"), and section 42 and 62 of the Companies Act, 2013, including the rules made thereunder, each as amended. The promoter's shareholding has decreased from 50.01% to 44.39% pursuant to the QIP issue.
- 6 The ICC International Court of Arbitration, London in terms of its order dated January 22, 2024 has pronounced an arbitration award to Celltrion Inc of \$3.05 Mn for breach of contract and Interest till the date of payment and legal cost of \$0.7 Mn which aggregating to Rs.3,738.63 Lakhs as on 30.06.2024. Celltrion has filed an execution petition before the High Court of Karnataka, Bengaluru on June 03, 2024. The Company is legally advised that it has sufficient grounds to challenge the order and has challenged the execution petition accordingly. Hence the ultimate outcome of the order cannot be determined presently. Therefore, the management is of the view that no provision is deemed necessary as of now in respect of this matter in the Financial Statements and the same is disclosed as a contingent liability.
- 7 The Operating segment of the Company is " Pharmaceuticals", as the Chief Operating Decision Maker reviews business performance at an overall Company level as one segment. Therefore, segment reporting as per Ind-AS 108 is not applicable to the Company.
- 8 **Events after the reporting period:** Shilpa Biologicals Pvt. Ltd. (SBPL), a wholly Owned Subsidiary of the Company on July 8, 2024 has allotted 23,40,000 equity shares of face value Rs.100/- each at a share premium of Rs.2,500/- per share, by way of rights issue to Shilpa Medicare Limited, its holding company against the pre-existing intercompany loan given by Shilpa Medicare Limited.
- 9 The figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year, which were subject to limited review.
- 10 Prior period/year figures have been reclassified wherever required to conform to the classification of the current period/year.

Date: 08.08.2024  
Place: Raichur

For and on behalf of the Board of Directors  
Shilpa Medicare Limited

  
Omprakash Inani  
Chairman  
DIN:01301385





**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors of Shilpa Medicare Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Shilpa Medicare Limited ("the Parent"), and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its associates for quarter ended June 30, 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended) ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We draw your attention to note no 06 in respect of unfavourable foreign arbitration award of Rs.3,738.63 Lakhs to Celltrion Inc by ICC International Court of Arbitration, London vide its order dated 22.01.2024 towards breach of contract along with legal cost and interest calculated upto June 30<sup>th</sup> 2024, Celltrion has filed an execution petition before the Honorable High court of Karnataka, Bengaluru, on June 03, 2024. Based on the legal advice, the Company has challenged the execution petition. Hence, the ultimate outcome of the order cannot be determined presently. Therefore, the management is of the view that no provision is deemed necessary as of now in respect of this matter in the Financial Statements and the same is disclosed as a contingent liability.

Our opinion is not modified in respect of this matter.

4. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial accounting matters, and applying analytical and other review procedures.





**BOHARA BHANDARI BUNG & ASSOCIATES LLP**  
CHARTERED ACCOUNTANTS

A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

5. The Statement includes the results of the following subsidiaries / Associates / Joint Ventures:

**A) Subsidiaries**

- i. Shilpa Pharma Lifesciences Limited (formerly known as Shilpa Corporate Holdings Private Limited)
- ii. Shilpa Therapeutics Private Limited
- iii. INM Technologies Private Limited
- iv. INM Nuvent Paints Private Limited (Step down subsidiary)
- v. Shilpa Biologicals Private Limited
- vi. Shilpa Biocare Private Limited (Formerly known as "Shilpa Albumin Private Limited")
- vii. Vegil Labs Private Limited
- viii. Shilpa Lifesciences Private Ltd (Step down subsidiary)
- ix. FTF Pharma Private Limited
- x. Makindus, Inc
- xi. Koanaa Healthcare Limited, UK
- xii. Koanaa Healthcare Limited, Austria
- xiii. Koanna Healthcare Canada Inc
- xiv. Indo Biotech SDN.BHD, Malaysia
- xv. Koanna International FZ-LLC, Dubai
- xvi. Koanna Healthcare, Spain S.L
- xvii. Shilpa Pharma Inc
- xviii. Pilnova Pharma Inc

**B) Joint Venture**

- i. Reva Medicare Private Limited
- ii. Sravathi Advance Process Technologies Private Limited
- iii. Sravathi AI Technologies Private Limited

**C) Associates**

- i. MAIA Pharmaceuticals, Inc





**BOHARA BHANDARI BUNG & ASSOCIATES LLP**  
CHARTERED ACCOUNTANTS

6. Based on our review conducted and procedures performed as stated in paragraph 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed; or that it contains any material misstatement.
7. We did not review the interim financial statements of two (02) subsidiaries included in the consolidated unaudited financial results, whose interim financial statements reflect as follows,

Particulars	(Rs. In Lakhs)
	Quarter ended June 30, 2024
Total Revenue	1006.77
Total Net profit/(loss) after tax	28.67
Total Comprehensive Income	31.52

These above interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

8. The accompanying statement includes the unaudited financial results of Nine (09) subsidiaries, whose interim financial results reflects as follows,

Particulars	(Rs. In Lakhs)
	Quarter ended June 30, 2024
Total Revenue	469.93
Total Net profit/(loss) after tax	(125.07)
Total Comprehensive Income	(125.07)





**BOHARA BHANDARI BUNG & ASSOCIATES LLP**  
CHARTERED ACCOUNTANTS

The unaudited interim financial results and other unaudited financial information of these subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the statement is not modified in respect of the above matter.

9. In case of one (01) foreign associate, interim financial statements for the quarter are not concluded and have not been furnished to us by the Management, and our opinion on the Consolidated Financial Statements, in so far as it relates to the amounts included in respect of this associate is based solely on the information available for the period ended March 31, 2024. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group.

Our conclusion on the statement is not modified in respect of the above matter.

**For Bohara Bhandari Bung And Associates LLP**  
Chartered Accountants  
Firm Regn No.008127S/S200013



**CA. Yogesh J.R. Bung**  
Partner  
M.No.143932

Place: Raichur

Date: 08-08-2024

UDIN: 24143932BKAESM7733